Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMILE: Maintenance of HIV suppression with elvitegravir + darunavir/ritonavir in children (PENTA 17)
2013-001476-37Phase 2Completed
- Sponsor
- Penta Foundation
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of elvitegravir, darunavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Penta Foundation. Primary endpoint: Virologic failure rate (HIV-1 RNA ≥ 50 copies/mL, confirmed). Started Oct 2015; status: completed.
02
Drugs
elvitegravirdarunavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2013-001476-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001476-37.